Recursion Pharmaceuticals (RXRX) Cash from Operations (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Cash from Operations data on file, last reported at 81101000.0 in Q1 2026.

• Quarterly Cash from Operations rose 38.54% year-over-year to 81101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 320952000.0 (up 17.46% YoY) and the FY2025 annual result came in at 371808000.0, down 3.52% from the prior year.
• Cash from Operations declined to 81101000.0 in Q1 2026, from 46073000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 77388000.0 in Q1 2022 to a low of 131957000.0 in Q1 2025.
• A 5-year average of 69611000.0 and a median of 73316000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations jumped 351.63% — and 2023, when it plunged 194.74%.
• Tracing RXRX's Cash from Operations over 5 years: stood at 44748000.0 in 2022, then tumbled by 65.54% to 74077000.0 in 2023, then slumped by 55.82% to 115430000.0 in 2024, then surged by 60.09% to 46073000.0 in 2025, then plunged by 76.03% to 81101000.0 in 2026.
• The last three Cash from Operations figures came in at 81101000.0 (Q1 2026), 46073000.0 (Q4 2025), and 117360000.0 (Q3 2025), per Business Quant data.